Orthocell Achieves Record FY26 Revenue as Remplir Gains Global Momentum
Orthocell Limited (ASX: OCC) reported its strongest annual financial performance to date, supported by rising global demand for its flagship nerve repair product, Remplir. The company generated record FY26 revenue of AU$13.2 million, representing a 44% increase over the previous year, while June quarter revenue climbed to a record AU$3.8 million, up 20% from the March quarter. In the United States, Remplir continued to strengthen its commercial presence, with quarterly sales reaching AU$0.33 million as distribution expanded across more than 20 states, covering approximately 50% of the population. Product adoption also increased, with 70 hospitals and 76 surgeons purchasing Remplir during the rollout. Orthocell ended the financial year with AU$44.1 million in available funds and no long-term debt, leaving it well positioned to support further expansion. The company expects additional growth through broader U.S. penetration, upcoming UK and European approvals, and continued development of its regenerative medicine portfolio.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Orthocell Achieves Record FY26 Revenue as Remplir Gains Global Momentum
Orthocell Limited (ASX: OCC) reported its strongest annual financial performance to date, supported by rising global demand for its flagship nerve repair product, Remplir. The company generated record FY26 revenue of AU$13.2 million, representing a 44% increase over the previous year, while June quarter revenue climbed to a record AU$3.8 million, up 20% from the March quarter. In the United States, Remplir continued to strengthen its commercial presence, with quarterly sales reaching AU$0.33 million as distribution expanded across more than 20 states, covering approximately 50% of the population. Product adoption also increased, with 70 hospitals and 76 surgeons purchasing Remplir during the rollout. Orthocell ended the financial year with AU$44.1 million in available funds and no long-term debt, leaving it well positioned to support further expansion. The company expects additional growth through broader U.S. penetration, upcoming UK and European approvals, and continued development of its regenerative medicine portfolio.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au